Downtime, Dollars & Data: Avoiding the Hidden Costs of Flow

Episode #32 of The Conversational Flow explores several significant developments shaping the flow cytometry and biopharmaceutical industries, including advances in antibody drug conjugates (ADCs), questions surrounding circadian timing in cancer treatment, and major life sciences acquisitions. Our hosts, Brian and Adam, discuss how improvements in ADC linker technology and broader first-line applications are helping revive interest in this therapeutic platform, while also examining why a rece...